CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis

被引：1
|
作者：
Soo, R. A. [1 ]
Cho, B. C. [2 ]
Kim, J-H. [3 ]
Ahn, M-J. [4 ]
Lee, K. H. [5 ,12 ]
Zimina, A. [6 ]
Orlov, S. [7 ]
Bondarenko, I. [8 ]
Lee, Y-G. [9 ]
Ni, L. Yueh [10 ]
Lee, S. S. [11 ]
Lee, K. H. [5 ,12 ]
Pang, Y. K. [13 ]
Fong, C. H. [14 ]
Kang, J. H. [15 ]
Lim, C. S. [16 ]
Danchaivijitr, P. [17 ]
Lee, H. [18 ]
Park, S. [18 ]
Cicin, I. [19 ]
机构：
[1] Natl Univ Canc Inst Singapore, Haematol Oncol Dept, Singapore, Singapore
[2] Yonsei Univ, Yonsei Canc Ctr, Internal Med, Coll Med, Seoul, South Korea
[3] CHA Bundang Med Ctr, Seongnam, South Korea
[4] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr, Sch Med, Seoul, South Korea
[5] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Dept Med, Coll Med, Cheongju, South Korea
[6] State Budgetary Healthcare Inst Omsk Reg, Omsk, Russia
[7] Pavlov State Med Univ, Oncol, St Petersburg, Russia
[8] Dnipropetrovsk Med Acad, Oncol & Med Radiol Dept, Dnipro, Ukraine
[9] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Sch Med, Seoul, South Korea
[10] Hosp Umum Sarawak, Sarawak, Malaysia
[11] Inje Univ, Haeundae Paik Hosp, Coll Med, Busan, South Korea
[12] Yeungnam Univ, Dept Internal Med, Med Ctr, Daegu, South Korea
[13] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia
[14] Hosp Pulau Pinang, Dept Radiotherapy & Oncol, Georgetown, Malaysia
[15] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med, Seoul, South Korea
[16] Hosp Sultan Ismail, Oncol Dept, Johor Baharu, Malaysia
[17] Mahidol Univ, Fac Med, Dept Med, Siriraj Hosp, Bangkok, Thailand
[18] Yuhan Corp, Seoul, South Korea
[19] Trakya Univ, Med Oncol Dept, Med Fac, Edirne, Turkiye
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2357
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1324MO
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors
    Halmos, Balazs
    Rai, Pragya
    Min, Jae
    Hu, Xiaohan
    Chirovsky, Diana
    Shamoun, Mark
    Zhao, Bin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [32] The efficacy and safety of osimertinib in patients with advanced EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled trials
    Tang, Xiumei
    Li, Weimin
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [33] Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced nonsmall cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial
    Cho, B. C.
    Felip, E.
    Spira, A. I.
    Girard, N.
    Lee, J. S.
    Lee, S. H.
    Ostapenko, Y. V.
    Danchaivijitr, P.
    Liu, B.
    Alip, A.
    Korbenfeld, E. P.
    Dias, J.
    Sun, T.
    Martinez, M.
    Bauml, J. M.
    Shreeve, M.
    Sethi, S.
    Knoblauch, R. E.
    Hayashi, H.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1306 - S1306
  • [34] Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis
    Kashizaki, Fumihiro
    Chen, Hao
    Miyasaka, Atsushi
    Tsuchiya, Nanami
    Yamada, Chihiro
    Okazaki, Shunsuke
    Kaneko, Mai
    Kano, Taiki
    Kameda, Yohei
    Kikuchi, Akitomo
    Yumoto, Kentaro
    Osawa, Hiroyuki
    Koizumi, Harumi
    Takahashi, Kenichi
    Kaneko, Takeshi
    CLINICAL LUNG CANCER, 2024, 25 (01) : e52 - e57.e2
  • [35] EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis (vol 24, 1390, 2024)
    Liu, Ao
    Wang, Xiaoming
    Wang, Lian
    Zhuang, Han
    Xiong, Liubo
    Gan, Xiao
    Wang, Qian
    Tao, Guanyu
    BMC CANCER, 2025, 25 (01)
  • [36] Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
    Ramalingam, S. S.
    O'Byrne, K.
    Boyer, M.
    Mok, T.
    Jaenne, P. A.
    Zhang, H.
    Liang, J.
    Taylor, I.
    Sbar, E. I.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 423 - 429
  • [37] COST-EFFECTIVENESS ANALYSIS OF AFATINIB VERSUS GEFITINIB IN EGFR-MUTATED POPULATION WITH ADVANCED NON-SMALL-CELL LUNG CANCER IN FRANCE
    de Pouvourville, G.
    Luciani, L.
    Le Lay, K.
    Po, P.
    Bennouna, J.
    Perol, M.
    Moro-Sibilot, D.
    Vergnengre, A.
    Chouaid, C.
    VALUE IN HEALTH, 2017, 20 (09) : A439 - A439
  • [38] Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis
    Girard, N.
    Leighl, N.
    Ohe, Y.
    Kim, T. M.
    Demirdjian, L.
    Bourla, A. B.
    Sultan, A. Abdul
    Mahadevia, P.
    Bauml, J. M.
    Sabari, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S51 - S52
  • [39] Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
    Leighl, Natasha B.
    Karaseva, Nina
    Nakagawa, Kazuhiko
    Cho, Byoung-Chul
    Gray, Jhanelle E.
    Hovey, Tina
    Walding, Andrew
    Ryden, Anna
    Novello, Silvia
    EUROPEAN JOURNAL OF CANCER, 2020, 125 : 49 - 57
  • [40] Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers
    Chouaid, Christos
    Luciani, Laura
    Lelay, Katell
    Do, Pascal
    Bennouna, Jaafar
    Perol, Maurice
    Moro-Sibilot, Denis
    Vergnenegre, Alain
    de Pouvourville, Gerard
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (10) : 1496 - 1502
12345